Baidu
map

世卫组织发布首份抗生素耐药细菌清单(附名单)

2017-03-01 佚名 医谷

近日,世界卫生组织(WHO)发表了首份抗生素耐药“重点病原体”清单,列出了对人类健康构成最大威胁的12种细菌种族目录,以指导和促进新型抗生素的研究与开发。



近日,世界卫生组织(WHO)发表了首份抗生素耐药“重点病原体”清单,列出了对人类健康构成最大威胁的12种细菌种族目录,以指导和促进新型抗生素的研究与开发。


此份清单中,特别强调了对多种抗生素存有耐药的革兰氏阴性细菌的威胁性问题,这些细菌具有寻找新方法抵抗治疗的内在能力,并且还可以传递使其它细菌产生耐药的遗传物质。

根据对新型抗生素的迫切需求程度,世卫组织将清单分为三个类别,即极为重要、十分重要和中等重要。其中,最为重要的一组包括耐多药细菌。这些细菌对于医院、养老院以及需要使用呼吸机和血液导管等装置进行护理的患者带来了直接威胁,可引起严重甚至致命的感染,如血流感染和肺炎。它们包括不动杆菌属、假单胞菌属和各种肠杆菌科(包括克雷伯氏菌属、大肠杆菌、沙雷氏菌属和变形杆菌属)。这些细菌已经对大量抗生素产生了耐药性,包括碳青霉烯类和第三代头孢菌素类药物——用于治疗耐多药细菌的最佳可用抗生素。

清单中的第二和第三个层级为“十分重要”和“中等重要”类别,包括其他一些日益出现耐药并引起更常见疾病的细菌,例如淋病和由沙门氏菌引起的食物中毒。

此外,结核病对传统治疗方法的耐药性近年来一直呈增长之势,世卫组织已将其归入其他专门规划工作目标,因此没有列入这份清单,同时也没有将甲型和乙型链球菌和衣原体等其它细菌纳入其中,因为这类细菌对现有治疗办法的耐药程度较低,且目前不会带来公共卫生重大威胁。

据了解,这份清单是世卫组织与德国蒂宾根大学传染病处合作开发完成的,使用的是经过国际专家审查的一组多标准决策分析技术。病原体的选择参照标准包括:所引起感染的致命程度;是否需要长期住院治疗;接触现有抗生素时出现耐药的频次;在动物之间、从动物到人以及人与人传播的容易程度;是否可以预防;还剩多少治疗选用方案;是否已有新的抗生素治疗方法处于研发过程中。

世卫组织卫生系统和创新助理总干事Marie-Paule Kieny博士表示:“这份清单是用来确保研发工作面向公共卫生紧急需求的新工具,抗生素耐药性问题日趋严重,我们的治疗选用办法正在快速耗尽。如果仅仅依靠市场力量来解决问题,我们最迫切需要的新型抗生素将不会得到及时开发。”

世卫组织同时指出,虽然更多的研发努力至关重要,但仅仅靠此并不能解决问题。为了解决耐药性问题,还必须更好地预防感染并在人间和动物中间适当使用现有抗生素,以及合理使用将来开发出来的任何新型抗生素。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1818571, encodeId=8ba418185e164, content=<a href='/topic/show?id=2c019e96631' target=_blank style='color:#2F92EE;'>#附名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97966, encryptionId=2c019e96631, topicName=附名单)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Feb 05 19:06:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724666, encodeId=b3f81e246661f, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Wed May 31 20:06:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300808, encodeId=52a51300808af, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441633, encodeId=da9e144163331, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1818571, encodeId=8ba418185e164, content=<a href='/topic/show?id=2c019e96631' target=_blank style='color:#2F92EE;'>#附名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97966, encryptionId=2c019e96631, topicName=附名单)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Feb 05 19:06:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724666, encodeId=b3f81e246661f, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Wed May 31 20:06:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300808, encodeId=52a51300808af, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441633, encodeId=da9e144163331, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1818571, encodeId=8ba418185e164, content=<a href='/topic/show?id=2c019e96631' target=_blank style='color:#2F92EE;'>#附名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97966, encryptionId=2c019e96631, topicName=附名单)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Feb 05 19:06:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724666, encodeId=b3f81e246661f, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Wed May 31 20:06:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300808, encodeId=52a51300808af, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441633, encodeId=da9e144163331, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1818571, encodeId=8ba418185e164, content=<a href='/topic/show?id=2c019e96631' target=_blank style='color:#2F92EE;'>#附名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97966, encryptionId=2c019e96631, topicName=附名单)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Feb 05 19:06:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724666, encodeId=b3f81e246661f, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Wed May 31 20:06:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300808, encodeId=52a51300808af, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441633, encodeId=da9e144163331, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Fri Mar 03 06:06:00 CST 2017, time=2017-03-03, status=1, ipAttribution=)]

相关资讯

哪些抗生素,孕妇不能用?

在临床上,我们经常遇到孕产妇的感染性疾病,需要使用抗生素。很多年轻临床大夫这时候心里就没谱,不知道哪些抗感染药物能用,哪些不能用。

儿童阑尾炎:抗生素或可替代手术

急性阑尾炎是儿童急诊进行手术的最常见的原因之一。然而对于国外的年轻家长而言,手术是价格昂贵且会令人担忧的。最近一项最新的对现有文献进行的荟萃分析发现,对于儿童阑尾炎使用抗生素进行治疗可能是一种安全有效的治疗策略。

世卫组织发布迫切需要新型抗生素的细菌清单

世卫组织27日发表了首份抗生素耐药“重点病原体”清单——这是对人类健康构成最大威胁的12种细菌种族目录。

Crit Care Med:哌拉西林-他唑巴坦血浆浓度测量的意义

肥胖和一些危重疾病影响抗生素的药代动力学,但哌拉西林-他唑巴坦连续静脉滴注的药物动力学在肥胖及危重病人中的研究很少。近期,一项发表在杂志Crit Care Med上的研究旨在比较哌拉西林在严重肥胖和非肥胖患者发生严重脓毒症或败血症休克时的药代动力学。此项研究是前瞻性对照研究。研究者们使用16g-2g / 24小时连续静脉滴注哌拉西林-他唑巴坦治疗危重性严重肥胖(体重指数> 35kg / m)

Natur子刊:中国农业大学院士研究组警示抗生素滥用问题

来自中国农业大学的沈建忠教授研究团队对中国的养殖场、屠宰场和超市进行了抽样调查,发现在中国家禽生产流程中普遍存在能让细菌对碳青霉烯和粘菌素产生耐药性的基因。

欧盟细菌抗生素耐药研究取得进展

细菌抗生素耐药已对现实社会构成严重威胁。当听到细菌抗生素耐药时,大部分人会想到“刀枪不入”的超级细菌。实际上细菌通常拥有休眠能力,当遇到外部环境压力时会创建自身毒素(蛋白质)导致细菌休眠,压力解除后创建另一毒素(又称抗毒素)结束休眠状态。药物抗生素一般只对“活着”或正在裂变的细菌产生作用,而对以细菌微生物膜形式出现的休眠细菌无任何作用。欧盟第七研发框架计划为此提供了全额资助进行研究。

Baidu
map
Baidu
map
Baidu
map